Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Treatment-cycle-resolved peripheral blood T-cell GP73 dynamics are associated with clinical benefit during PD-1/PD-L1 inhibitor-based therapy in NSCLC.

Created on 15 Nov 2026

Authors

Xin Feng, Hongbin Song, Dandan Zhang, Lanlan Liu, Xiaoli Wang, Jinmei Zhang, Xing Mu, Nan Hao, Yuanyuan Zhang, Deyong Zou, Cuijuan Duan, Xiaoli Yang

Published in

Lung cancer (Amsterdam, Netherlands). Volume 222. Pages 109682. Nov 05, 2026. Epub Nov 05, 2026.

Abstract

Single-time-point tissue-based biomarkers incompletely capture evolving immune states during immunotherapy. This study aimed to dynamically characterize associations linking GP73 levels in peripheral blood T cells and serum to PD‑1/PD-L1 inhibitor response and clinical outcomes in NSCLC patients treated with PD‑1/PD-L1 inhibitor-based therapy.
Intracellular T-cell GP73 was quantified by flow cytometry in available samples from 76 patients from baseline through up to eight cycles. Early sampling was days 1-7; late sampling was day 18 until before the next administration. Mixed-effects models, ROC analyses, and delayed-entry Cox regression assessed dynamics, prespecified study-defined clinical benefit, and progression-free survival (PFS), respectively. Conventional RECIST 1.1 objective response was a sensitivity endpoint.
T-cell GP73 declined within cycles (P = 0.012) and rebounded between cycles (P < 0.001). Between-cycle changes differed by clinical benefit status (interaction P < 0.001), unlike within-cycle changes (interaction P = 0.181). T-cell GP73 was higher with clinical benefit (both P < 0.001), with early- and late-window AUCs of 0.865 and 0.772, respectively. RECIST 1.1 sensitivity analyses retained a between-cycle interaction (P = 0.005) and early- and late-window objective-response discrimination (AUCs = 0.761 and 0.808). Serum GP73 showed limited discrimination (AUC = 0.571) and no significant correlation with T-cell GP73 (P = 0.432). Higher late-window T-cell GP73 was associated with longer PFS (delayed-entry Cox HR per 100-MFI increase = 0.63, 95 % CI 0.44-0.93; P = 0.018).
Treatment-cycle-resolved T-cell GP73 monitoring revealed clinical benefit-associated dynamics, while L-window GP73 levels were associated with clinical benefit and progression-free survival in NSCLC.

PMID:
43033551
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement